FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to the field of chemical and pharmaceutical industry and medicine and pertains to a pharmaceutical composition and a medicinal product exhibiting preventive and/or therapeutic antiviral activity, as well as an application thereof. Pharmaceutical composition contains therapeutically effective amounts of favipiravir in the form of a free base and at least one proteinogenic amino acid at a favipiravir:amino acid mass ratio of 1.0:0.1 to 1.0:1.2, respectively. Medicinal product contains the above pharmaceutical composition and at least one pharmaceutically acceptable excipient. Also proposed is an application of the above pharmaceutical composition or medicinal product for treating and/or preventing viral infections.
EFFECT: expanded range of antiviral agents; above pharmaceutical composition and medicinal product have improved process characteristics, stability, and bioavailability.
60 cl, 2 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AMINO ACID, DRUG CONTAINING IT, AS WELL AS THEIR USE FOR TREATING AND/OR PREVENTING VIRAL INFECTIONS | 2022 |
|
RU2814927C1 |
| ANTIVIRAL PHARMACEUTICAL COMPOSITION CONTAINING FAVIPIRAVIR AND AMINO ACID HYDRATE AND/OR ITS PHARMACEUTICALLY ACCEPTABLE SALT | 2021 |
|
RU2789612C1 |
| PHARMACEUTICAL COMPOSITION AND MEDICINAL AGENT CONTAINING NOVEL DERIVATIVES OF FAVIPIRAVIR | 2023 |
|
RU2832326C1 |
| METHOD OF PRODUCING NOVEL DERIVATIVES OF FAVIPIRAVIR | 2023 |
|
RU2828875C1 |
| ANTIVIRAL COMPOSITION | 2020 |
|
RU2740660C1 |
| ANTIVIRAL COMPOSITION | 2020 |
|
RU2740657C1 |
| ANTI-RNA VIRAL, INCLUDING ANTI-CORONAVIRUS AGENT - SUBSTITUTED QUINOXALINE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS | 2020 |
|
RU2744429C1 |
| ANTIVIRAL COMPOSITION | 2020 |
|
RU2751108C1 |
| ANTI-COVID-19 (SARS-COV-2) VIRAL PHARMACEUTICAL COMPOSITION | 2020 |
|
RU2731932C1 |
| NOVEL CRYSTALLINE FORM OF [(2R,3S,4R,5R)-3,4-DIHYDROXY-5-[4-(HYDROXYAMINO)-2-OXOPYRIMIDIN-1-YL]OXOLAN-2-YL]METHYL-2-METHYLPROPANOATE | 2021 |
|
RU2835426C2 |
